GLP-1 Treatment and Muscle Loss: What Matters Beyond the Scale

Weight loss during GLP-1 treatment can include a reduction in lean tissue as well as fat. The effect on your strength and daily functioning needs separate attention. A body-composition percentage cannot answer every question about muscle health, and it does not predict what will happen to you.

A useful care plan follows how you eat, move and function alongside the weight trend. That gives you something more actionable to discuss than an alarming “muscle loss” headline.

Lean mass, muscle and strength describe different things

Lean mass includes muscle and other non-fat tissues. Strength describes what your muscles can do; physical function concerns tasks such as standing and moving around. Studies use different measurements, so their results need those labels attached. The joint GLP-1 nutrition advisory discusses lean tissue, muscle and function as related but distinct considerations.

A measurement	What it can help describe	What it cannot establish on its own
Body weight	The total change on the scale	How much change came from fat versus lean tissue
DXA lean-mass estimate	Body-composition change using a scan	A direct measurement of all skeletal muscle or strength
Muscle imaging	Size or composition of a measured region	How every muscle performs in everyday life
Grip or chair-rise testing	Performance on a particular task	Every aspect of fitness, balance or independence

These distinctions are visible in studies that measure body composition and function separately, including SEMALEAN and STEP UP. A trend should be interpreted with the method, symptoms and clinical context.

What have GLP-1 studies actually found?

In the SURMOUNT-1 DXA substudy, 160 participants had measurements at baseline and 72 weeks. With pooled tirzepatide doses, average fat mass declined 33.9% and lean mass 10.9%. About three-quarters of the weight lost was fat and one-quarter lean mass; the proportions were similar in the placebo group. These figures are group results from a subset of the trial, not a prediction that a quarter of your weight loss will be skeletal muscle. Published substudy.

The SEMALEAN prospective study, published in 2026, followed people receiving semaglutide. Among 106 completers, lean mass declined during the first seven months and then stabilized, while handgrip strength improved over 12 months. It was not a randomized comparison with untreated participants, so it cannot isolate a medication effect. It does show why a change in lean mass and a change in strength should not be treated as identical. SEMALEAN results.

A September 2026 STEP UP secondary analysis used imaging and a chair-rise test. The pooled semaglutide groups had reduced muscle volume and muscle fat infiltration over time, while chair-rise performance was preserved. Some between-group differences in tissue volumes were not statistically significant. A single functional test and a secondary analysis do not establish that everyone maintains muscle function. STEP UP analysis.

These studies differ in population, design and measurements. They cannot support a fair ranking of medicines for muscle preservation. Our semaglutide and tirzepatide comparison keeps treatment comparisons in their wider context.

Build support around food and suitable movement

Discuss enough nourishment and an appropriate protein intake with your clinician or registered dietitian. The four-society advisory supports combining nutrition with structured resistance exercise; a protein supplement alone does not provide the same plan. Neither approach guarantees that lean mass will stay unchanged. Joint advisory.

Our GLP-1 meal guide and weekly worksheet can help translate that conversation into ordinary meals. Ask for an individualized protein goal, especially if you already follow a medical nutrition plan.

For adults with chronic conditions or disabilities who are able, CDC guidance includes at least two days of muscle-strengthening activity each week, alongside aerobic activity. It also advises matching activity to ability and consulting a professional about appropriate amounts and types. This is a general health recommendation, not a personalized rehabilitation program. CDC guidance.

Resistance bands, weights and some body-weight exercises can count as strengthening work. Which exercises, resistance and progression fit you should reflect your starting ability, injuries and health conditions. CDC activity examples.

A short check-in beyond body weight

Choose observations you can describe consistently, without attempting a strenuous self-test. This is a conversation worksheet, not a diagnostic score.

Bring to the review	An example of a useful note
An everyday task	“Carrying my usual grocery bag feels harder than last month.”
Meal consistency	“Lunch has become difficult on workdays.”
Activity you already do	“I completed my agreed routine, but needed longer rests.”
Symptoms and timing	“I felt weak after several days of nausea.”
A practical barrier	“I need a plan that works at home without gym equipment.”
A question	“Would a strength assessment or dietitian appointment change our plan?”

New or worsening weakness deserves a medical conversation; don’t assume a scan result or medication explains it. If tiredness is the main concern, our fatigue guide helps organize symptoms and when to seek help.

Make the next decision with your care team

Ask which measures are useful for your situation, how often to review them, and what finding would change the plan. A useful appointment should end with a specific next step and a follow-up date. If weight loss has slowed, use the plateau checklist alongside these functional observations.

The peptide field guide separates documented effects from discussion topics. Its “muscle and strength” tags do not establish that an additional peptide prevents muscle loss. For ongoing care, include nutrition and activity support in your total-cost comparison, and ask what is actually included before paying.

Sources and further reading

1. SURMOUNT-1: Body composition changes during weight reduction with tirzepatide, 2025 (opens in a new tab)
2. SEMALEAN: Semaglutide, fat mass, lean mass and muscle function, 2026 (opens in a new tab)
3. STEP UP: Thigh skeletal muscle, fat infiltration and physical function, September 2026 (opens in a new tab)
4. Four-society advisory: Nutritional priorities to support GLP-1 therapy for obesity, 2025 (opens in a new tab)
5. CDC: Physical activity for adults with chronic conditions and disabilities (opens in a new tab)
6. CDC: What counts as physical activity for adults (opens in a new tab)

Sources checked October 8, 2026. Prices, labels and policies can change. Linked studies being peer reviewed does not mean this article has been clinically reviewed.